Progenics Pharmaceuticals, Inc. Acquires Molecular Insight Pharmaceuticals, Inc. to Expand Oncology-Focused Pipeline

Published: Jan 22, 2013

TARRYTOWN, N.Y., Jan. 22, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that it has acquired Molecular Insight Pharmaceuticals, Inc., a clinical-stage private biotechnology company with a small molecule chemistry pipeline aimed at enhancing cancer treatment.

Back to news